David J. Chung - Concepedia

Author

David J. Chung

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

D Chung, D J Chung, D. Chung, D. J. Chung, D.J. Chung, Daniel Thomas Chung, David J. Chung, David Chung, David J Chung, David J. Chung

344

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Kettering University Sylvester Comprehensive Cancer Center University of Miami

About

David J. Chung is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, hematology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	802
2	Health Sciences	8	8	526
3	Natural Sciences	1	1	22
4	Public Health	1	1	13
5	Allergy	1	1	36

David J. Chung

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Indoleamine 2,3-dioxygenase–expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells David J. Chung, Marco Rossi, Emanuela Romano, Blood	2009	259
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy David J. Chung, Katherine B. Pronschinske, Justin A. Shyer, Cancer Immunology Research T-regulatory CellImmunologyImmunoeditingT CellsImmunotherapy	2015	195
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma Ola Landgren, Malin Hultcrantz, Benjamin Diamond, JAMA Oncology	2021	114
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial Sham Mailankody, Arnab Ghosh, Terence J. Purdon, Blood	2018	99
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial Benjamin Diamond, Neha Korde, Alexander M. Lesokhin, The Lancet Haematology Hematological MalignancyOncologyContinuous Lenalidomide MaintenanceHematologyMyeloid Neoplasia	2021	87
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma Nikoletta Lendvai, Patrick Hilden, Sean M. Devlin, Blood	2014	82
Accelerated single cell seeding in relapsed multiple myeloma Heather Landau, Venkata D. Yellapantula, Benjamin Diamond, Nature Communications	2020	78
Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study Niloufer Khan, Sarah Lindner, Antonio L. C. Gomes, Blood	2020	78
Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation <i>In Vitro</i> , Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells <i>In Vivo</i> Emanuela Romano, Marco Rossi, Gudrun Ratzinger, Clinical Cancer Research	2011	74
Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood Kazunori Murata, Samuel I. McCash, Brittany L. Carroll, Clinical Biochemistry Hematological MalignancyBone Marrow FailureAutoimmune DiseaseMalignant Blood DisorderHematology	2016	67

Page 1